Literature DB >> 21291788

Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD.

Haseeb Jafri1, Alawi A Alsheikh-Ali, Paula Mooney, Carey D Kimmelstiel, Richard H Karas, Jeffrey T Kuvin.   

Abstract

BACKGROUND: The importance of the number of circulating low-density lipoprotein (LDL) cholesterol particles, in addition to total LDL level, has been increasingly recognized. The effects of extended-release niacin (ERN) on LDL particle numbers have not been studied.
OBJECTIVE: To evaluate ERN's effects on LDL particle numbers.
METHODS: Fifty-four patients with stable coronary artery disease (CAD) and well-controlled LDL levels were randomly assigned to 3 months of ERN (1 g/day) or placebo in addition to their baseline medications. Lipoprotein particle number was analyzed by proton nuclear magnetic resonance spectroscopy at baseline and after 3 months.
RESULTS: Compared to baseline, the addition of ERN had no significant effect on total LDL cholesterol levels; however, ERN decreased the number of medium and small LDL particles (P < .005). After 3 months, ERN decreased the number of medium and small LDL particles compared to placebo-treated patients (P < .05). ERN raised HDL cholesterol levels by 2.7%, significantly increased the number of large HDL particles (P < .001), and decreased the number of small HDL particles (P = .027) compared to placebo. There were no significant changes in lipid values or particle numbers in the placebo-treated patients. In patients with stable coronary artery disease and well-controlled LDL cholesterol levels, ERN reduced the number of circulating particles of the more atherogenic subtypes of LDL, despite having no effect on total LDL cholesterol levels. ERN also favorably altered the number of HDL particles.
CONCLUSION: ERN-induced alterations in lipoprotein particle numbers may contribute to its anti-atherosclerotic effects, and these effects may not be evident from the standard lipid profile.

Entities:  

Year:  2008        PMID: 21291788     DOI: 10.1016/j.jacl.2008.12.003

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  14 in total

1.  Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.

Authors:  Graziella E Ronsein; Patrick M Hutchins; Daniel Isquith; Tomas Vaisar; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

Review 2.  Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

Authors:  Preethi Mani; Anand Rohatgi
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

3.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

4.  Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome.

Authors:  James Kyle Taylor; Eric P Plaisance; A Jack Mahurin; Michael L Mestek; Jose Moncada-Jimenez; Peter W Grandjean
Journal:  Redox Rep       Date:  2014-09-02       Impact factor: 4.412

5.  High density lipoprotein and cardiovascular diseases.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-07-26

6.  High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.

Authors:  Robert W McGarrah; Damian M Craig; Carol Haynes; Z Elaine Dowdy; Svati H Shah; William E Kraus
Journal:  Atherosclerosis       Date:  2016-01-11       Impact factor: 5.162

7.  The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia.

Authors:  Robert H Knopp; Barbara M Retzlaff; Brian Fish; Alice Dowdy; Barbara Twaddell; Thuy Nguyen; Pathmaja Paramsothy
Journal:  J Clin Lipidol       Date:  2009       Impact factor: 4.766

8.  Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.

Authors:  William Insull; Peter P Toth; H Robert Superko; Roopal B Thakkar; Scott Krause; Ping Jiang; Rhea A Parreno; Robert J Padley
Journal:  Vasc Health Risk Manag       Date:  2010-11-24

Review 9.  Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values.

Authors:  Robert S Rosenson; James A Underberg
Journal:  Cardiovasc Drugs Ther       Date:  2013-10       Impact factor: 3.727

10.  Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.

Authors:  Ngoc-Anh Le; Ran Jin; Joanne E Tomassini; Andrew M Tershakovec; David R Neff; Peter W F Wilson
Journal:  J Am Heart Assoc       Date:  2013-08-07       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.